MCF7A BCAR3 [MCF7-BCAR3] cell line
Invented at Erasmus Medical Center
- Datasheet
- References (1)
- Inventor Info
Info
| Catalogue Number | 154637 |
| Antigen/Gene or Protein Targets | BCAR3 |
| Parental Line | MCF7A |
| Synonyms | Breast Cancer Anti-Estrogen Resistance 3; SH2 Domain-Containing Protein 3B; NSP2 |
| Host | Human |
| Tissue | Breast |
| Disease Keywords | Mammary adenocarcinoma, estrogen-dependent |
| Model | Cancer Model |
| Relevance |
Breast cancer is widely and effectively treated with endocrine treatment. However, in many disease cases the tumours will eventually progress into an estrogen-independent and therapy-resistant phenotype Seven genes including AKT1, AKT2, BCAR1, BCAR2, BCAR3, EGFR2 and GRB7 have been shown to directly underlie estrogen independence in MCF7A human breast cancer cells. This cell line is part of a panel of 4 cell lines (Cat No 154636-154638, 154643) which have been transfected with these genes, plus the parental (Cat No 154546) These cell lines are a powerful tool for studying the molecular and cellular mechanisms of breast tumour progression, therapy resistance and to test the effectiveness of novel drugs to combat different modes of anti-estrogen insensitivity |
| Production Details | Full length BCAR3 cDNA was introduced in the estrogen-dependent MCF7A cell line by transfection with lipofectamine |
| Research Area | Cancer, Drug Discovery & Development |
| Recommended Growing Conditions | RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS) |
| Notes | This cell line is also resistant to Geneticin which may be included in the culture to maintain the expression plasmid |
